USA

USA

INDIA

India

BANGLADESH

BANGLADESH

NEPAL

Nepal

FIJI

FIJI

PAKISTAN

Pakistan

Melody Media Productions

Excellence in Broadcasting!

Pervez Saleem

(Producer/Director)

New revolutionary drug fully cures bowel cancer in patients

Courtesy: Geo News

New bowel cancer drug effective in 100% of cases, sparing patients the need for surgery and chemotherapy

A new immunotherapy drug has given promising results in the treatment of bowel cancer, striking out the need for patients to get surgery and chemotherapy.

The new drug called Jemperli, also known as dostarlimab, showed “unprecedented results” as it fully cured bowel cancer in patients, proving effective in 100% of cases, The Sun reported.

According to data presented at the American Society of Clinical Oncology (ASCO) conference in Chicago, every patient on the medication had locally advanced mismatch repair deficient (dMMR) rectal cancer, a form of bowel cancer.

Jemperli is already approved on the National Health Service (NHS) for women with some types of advanced or recurrent womb cancer.

A US trial led by Memorial Sloan Kettering Cancer Centre has found that all 42 patients have responded to treatment, with no tumours detected on scans.

Studies suggest (dMMR) rectal cancer accounts for five to 10% of all rectal cancers.

Hesham Abdullah, a senior vice president at GSK — the company that made the drug — said: “The data showing no evidence of disease in 42 patients is remarkable.”

Currently, patients with this type of cancer are treated via chemotherapy plus radiation, followed by surgery.

Andrea Cercek, principal investigator for the phase II study, said the new treatment showed “durable complete tumour regression without the need for life-altering treatment”.

She added: “As a clinician, I’ve seen firsthand the debilitating impact of standard treatment of dMMR rectal cancer. I am thrilled about the potential of dostarlimab in these patients.”

1- Header image: New drug strikes out need for surgery and chemotherapy for bowel cancer patients. — Unsplash

Disclaimer:
Sada-E-Watan provides news and opinion articles as a service to our readers. These articles and news items come from sources outside of our organization. Where possible, the author and the source are documented within each article. Statements and opinions expressed in these articles are solely those of the author (reporter/newspaper) or authors (reporters/newspapers) and may or may not be shared by the staff and management of Sada-E-Watan. Sada-E-Watan was created to provide one convenient central location where a user can quickly scan headlines from many news sources. The headlines listed on Sada-E-Watan pages are links to stories on the sites where these stories are located. The goal of Sada-E-Watan is to help readers access stories on web sites that they would normally not have time to view on a regular basis and to add value to the news source sites by mentioning their name on top, so readers can view these sites..

The Sada-E-Watan takes no responsibility for any loss or damage suffered as a result of using the linked websites or as a result of using the information published on any of the pages of the linked websites.

Whilst every effort is made to ensure downloadable content is free from viruses, Sada-E-Watan cannot accept any liability for damages resulting from virus infection. You should take adequate steps to ensure your virus check regularly when using any device.

If you have any questions or comments about Sada-E-Watan, please contact us at: radio@sada-e-watan.com